Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

BACKGROUND: Combined inhibition of epidermal growth factor receptor (EGFR) and Src family kinases (SFK) may lead to improved therapeutic effects. We evaluated the combination of dasatinib, an inhibitor of SFK and other kinases, and cetuximab, an anti-EGFR monoclonal antibody. PATIENTS AND METHODS: P...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Argiris, Athanassios, Feinstein, Trevor M., Wang, Lin, Yang, Tianbing, Agrawal, Shruti, Appleman, Leonard J., Stoller, Ronald G., Grandis, Jennifer R., Egloff, Ann Marie
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3402509/
https://ncbi.nlm.nih.gov/pubmed/21881918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9732-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars